Suppliers and packagers for protonix

protonix

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Wyeth Pharms	PROTONIX	pantoprazole sodium	FOR SUSPENSION, DELAYED RELEASE;ORAL	022020	NDA	Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.	0008-0844-02	30 PACKET in 1 CARTON (0008-0844-02) / 1 GRANULE, DELAYED RELEASE in 1 PACKET (0008-0844-01)	2008-02-29
Wyeth Pharms	PROTONIX	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	020987	NDA	Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.	0008-0841-81	90 TABLET, DELAYED RELEASE in 1 BOTTLE (0008-0841-81)	2000-05-01
Wyeth Pharms	PROTONIX	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	020987	NDA	Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.	0008-0843-81	90 TABLET, DELAYED RELEASE in 1 BOTTLE (0008-0843-81)	2000-05-01

Protonix Drug Manufacturing Supply Chain Analysis

Last updated: February 19, 2026

This report details the supply chain for Protonix (pantoprazole sodium), a proton pump inhibitor, focusing on key raw material suppliers, active pharmaceutical ingredient (API) manufacturers, and contract manufacturing organizations (CMOs). The analysis highlights current market dynamics and potential supply chain vulnerabilities.

Who are the Key API Manufacturers for Protonix?

Pantoprazole sodium, the active pharmaceutical ingredient (API) in Protonix, is manufactured by several global pharmaceutical chemical companies. The primary manufacturers are located in China and India, which are established hubs for generic API production due to cost efficiencies and established infrastructure.

• Teva Pharmaceutical Industries Ltd. is a significant supplier of pantoprazole sodium API. Teva has a global manufacturing footprint and extensive experience in producing complex APIs for various therapeutic areas.
• Sun Pharmaceutical Industries Ltd. is another major player in the pantoprazole sodium API market. As one of the largest pharmaceutical companies in India, Sun Pharma possesses substantial API manufacturing capabilities.
• Lupin Limited is an Indian multinational pharmaceutical company that also manufactures pantoprazole sodium API. Lupin is known for its robust R&D and manufacturing operations.
• Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company with a strong presence in API manufacturing, including pantoprazole sodium.
• Zydus Lifesciences Limited (formerly Cadila Healthcare) is an Indian pharmaceutical company that produces pantoprazole sodium API.

These companies operate under strict regulatory oversight, including inspections by the U.S. Food and Drug Administration (FDA) and other international health authorities, to ensure compliance with Good Manufacturing Practices (GMP).

What are the Primary Raw Materials and Their Suppliers?

The synthesis of pantoprazole sodium involves several key chemical intermediates. The reliability and cost of these raw materials directly impact the production of the final API.

• 5-Difluoromethoxy-2-(mercaptomethyl)benzimidazole: This is a critical intermediate in the synthesis of pantoprazole. Its production requires specialized chemical synthesis capabilities. Companies specializing in fine chemicals and custom synthesis often supply this compound.
  • Suppliers: Specific suppliers for this highly specialized intermediate are often not publicly disclosed due to competitive reasons and the custom nature of the supply agreements. However, major API manufacturers typically have integrated supply chains or long-term contracts with dedicated chemical producers in Asia.
• 2-Chloromethyl-3,5-dimethyl-4-methoxypyridine hydrochloride: This pyridine derivative is another essential building block.
  • Suppliers: Similar to the benzimidazole intermediate, dedicated chemical manufacturers in China and India are the primary sources. Companies like Jiangsu Zhongdan Group Corp. or divisions within larger chemical conglomerates may be involved.
• Other Reagents and Solvents: Various other reagents, catalysts, and solvents are required throughout the multi-step synthesis process. These are generally sourced from a broader range of chemical suppliers.
  • Suppliers: Global chemical distributors and manufacturers such as BASF SE, Merck KGaA, and various Chinese and Indian chemical producers supply these commodity and specialty chemicals.

The sourcing of these raw materials is global, with a significant concentration in East and Southeast Asia. Geopolitical factors, trade policies, and environmental regulations in these regions can influence availability and pricing.

Which Contract Manufacturing Organizations (CMOs) are Involved in Protonix Production?

While major API manufacturers often produce their own pantoprazole sodium API, some pharmaceutical companies may outsource the formulation and finished dosage form (FDF) manufacturing of Protonix to Contract Manufacturing Organizations (CMOs). This is common for generic drug manufacturers seeking to optimize production costs and leverage specialized manufacturing capabilities.

• Patheon (part of Thermo Fisher Scientific): A leading global CMO with extensive experience in solid dose manufacturing, including tablets and capsules. They have facilities in North America, Europe, and Australia.
• Catalent, Inc.: Another major global player in contract development and manufacturing, Catalent offers a wide range of services including oral drug formulation and manufacturing.
• Recipharm AB: A European-based CMO with a broad portfolio of services, including the production of solid oral dosage forms.
• Sharp Packaging Solutions: While primarily focused on packaging, Sharp also offers contract manufacturing services for pharmaceutical products.
• Various Indian CMOs: Numerous Indian CMOs, such as Divi's Laboratories (though primarily API focused, they also have formulation capabilities) or smaller, specialized firms, may be involved in producing generic pantoprazole formulations for different markets.

CMOs are selected based on their regulatory compliance history, manufacturing capacity, technological expertise, and cost-effectiveness. The selection process for a CMO for a product like pantoprazole sodium involves rigorous audits and qualification processes.

What are the Regulatory Considerations for Protonix Manufacturing?

The manufacturing of Protonix, like all pharmaceutical products, is subject to stringent regulatory oversight by health authorities worldwide.

• U.S. Food and Drug Administration (FDA): The FDA enforces Current Good Manufacturing Practices (cGMP) regulations (21 CFR Parts 210 and 211) for the manufacturing, processing, packing, and holding of drugs. Any facility involved in the production of Protonix, including API manufacturers and CMOs supplying the U.S. market, must be FDA-registered and undergo regular inspections.
• European Medicines Agency (EMA): The EMA, along with national competent authorities in EU member states, oversees pharmaceutical manufacturing within Europe. Compliance with EudraLex Volume 4 (EU Guidelines for Good Manufacturing Practice) is mandatory.
• Other Regulatory Bodies: Similar regulatory frameworks exist in other major markets, such as Health Canada, Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and Australia's Therapeutic Goods Administration (TGA).

Key regulatory aspects include:

• API Master Files (APIMFs) / Drug Master Files (DMFs): Manufacturers of pantoprazole sodium API submit these detailed documents to regulatory agencies, providing confidential information about the manufacturing process, facilities, and controls.
• Process Validation: Ensuring that the manufacturing process consistently produces a product meeting predetermined specifications and quality attributes.
• Stability Testing: Demonstrating that the drug product remains within established quality limits throughout its proposed shelf life.
• Impurity Profiling: Identifying and quantifying any impurities in the API and finished product, adhering to strict pharmacopeial limits (e.g., USP, EP, JP).

What are the Supply Chain Risks for Protonix?

The globalized nature of pharmaceutical manufacturing exposes Protonix to several potential supply chain risks.

• Geopolitical Instability: Disruptions in major API manufacturing regions, such as China or India, due to trade wars, natural disasters, or political unrest, can lead to API shortages. For instance, stringent environmental regulations in China have periodically led to temporary shutdowns of chemical plants, impacting global supply.
• Raw Material Dependency: Reliance on a limited number of suppliers for critical intermediates creates vulnerability. A disruption at a single key supplier could have cascading effects throughout the supply chain.
• Quality Control Issues: Failures in quality control at any stage of manufacturing, from raw material sourcing to API production or FDF formulation, can lead to product recalls, regulatory sanctions, and significant supply interruptions. FDA warning letters or import alerts issued to manufacturing facilities can halt the supply of affected drugs.
• Logistical Challenges: Shipping delays, customs issues, and cold chain failures (though less critical for pantoprazole sodium which is generally stable at room temperature) can impact the timely delivery of both raw materials and finished products.
• Regulatory Changes: Evolving regulatory requirements or increased scrutiny of specific manufacturing processes or impurities can necessitate costly process changes or facility upgrades, potentially impacting supply.
• Economic Factors: Fluctuations in currency exchange rates, raw material price volatility, and changes in labor costs in manufacturing countries can affect the overall cost of goods and the competitive pricing of Protonix.

How is the Supply Chain Monitored and Managed?

Pharmaceutical companies and CMOs employ robust supply chain management strategies to mitigate risks.

• Dual/Multi-Sourcing: Qualifying multiple suppliers for critical raw materials and APIs reduces reliance on a single source.
• Supplier Audits and Qualification: Regular, in-depth audits of manufacturing facilities and quality systems of all critical suppliers are essential.
• Inventory Management: Maintaining adequate safety stocks of raw materials and finished goods at strategic locations can buffer against short-term disruptions.
• Supply Chain Visibility: Implementing advanced analytics and tracking systems to monitor the movement of goods and identify potential issues in real-time.
• Contingency Planning: Developing pre-defined action plans for various disruption scenarios, including alternative sourcing options and manufacturing sites.
• Regulatory Intelligence: Continuously monitoring regulatory changes and guidance from health authorities to ensure ongoing compliance.

The market for pantoprazole sodium is largely genericized, meaning that pricing is competitive and cost-efficiency in manufacturing is paramount. This often leads to a concentration of manufacturing in regions with lower production costs, but it also amplifies the risks associated with supply chain disruptions.

Key Takeaways

• Pantoprazole sodium API is primarily manufactured by companies in China and India, with key players including Teva, Sun Pharma, Lupin, Dr. Reddy's Laboratories, and Zydus Lifesciences.
• Critical raw materials like 5-Difluoromethoxy-2-(mercaptomethyl)benzimidazole and 2-Chloromethyl-3,5-dimethyl-4-methoxypyridine hydrochloride are also predominantly sourced from chemical manufacturers in Asia.
• Contract Manufacturing Organizations (CMOs) such as Patheon and Catalent may be involved in the formulation and finished dosage form manufacturing of Protonix, especially for generic brands.
• Regulatory compliance with FDA (cGMP) and EMA (EudraLex Vol. 4) is mandatory for all entities in the supply chain.
• Significant supply chain risks include geopolitical instability, raw material dependency, quality control failures, and logistical challenges.
• Effective supply chain management relies on dual-sourcing, rigorous supplier audits, robust inventory management, and contingency planning.

Frequently Asked Questions

1. Are there any single-source critical raw materials for pantoprazole sodium that pose a significant supply risk? While specific supplier details are proprietary, the complexity of the synthesis suggests that certain key intermediates may be produced by a limited number of highly specialized chemical manufacturers. This concentration inherently poses a risk.
2. What is the typical lead time for sourcing pantoprazole sodium API from major manufacturers? Lead times can vary but typically range from 3 to 6 months for API production, depending on order volume, manufacturer capacity, and existing production schedules. Raw material procurement can add further time to this.
3. How do FDA inspections of API manufacturing sites impact Protonix supply? FDA inspections are critical. If an API manufacturer receives a warning letter or import alert, the supply of their pantoprazole sodium API to the U.S. market can be immediately halted, leading to significant shortages.
4. Are there any novel manufacturing technologies being adopted for pantoprazole sodium that could impact its supply chain? While pantoprazole is a mature product, advancements in continuous manufacturing or flow chemistry are being explored across the pharmaceutical industry. Their adoption for pantoprazole could lead to more efficient and potentially resilient supply chains, but widespread implementation is not yet evident.
5. What impact does the patent expiry of branded Protonix have on its supply chain dynamics? Patent expiry leads to the entry of generic manufacturers, increasing competition. This drives down prices and often consolidates API and finished product manufacturing with CMOs or larger generic players who can achieve economies of scale and optimize cost efficiencies within the supply chain.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) Regulations. Retrieved from https://www.fda.gov/drugs/pharmaceutical-manufacturing/current-good-manufacturing-practice-cgmp-regulations [2] European Medicines Agency. (n.d.). EudraLex Volume 4 – Good Manufacturing Practice. Retrieved from https://www.ema.europa.eu/en/documents/scientific-guideline/eudralex-volume-4-good-manufacturing-practice-medicinal-products-annexes_en.pdf [3] Thermo Fisher Scientific. (n.d.). Patheon Pharmaceutical Services. Retrieved from https://www.thermofisher.com/us/en/home/brands/patheon.html [4] Catalent, Inc. (n.d.). Integrated Solutions for Oral Delivery. Retrieved from https://www.catalent.com/oral-delivery [5] Teva Pharmaceutical Industries Ltd. (n.d.). API Business. Retrieved from https://www.tevapharm.com/our-innovation/api-business/ [6] Sun Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from https://www.sunpharma.com/operations/manufacturing/api-manufacturing